Brought to you by 
Merck, Pierre Fabre Medicament sign oncology deal
10 Aug 2004
Executive Summary
Merck and Pierre Fabre Medicament signed a research, development, and licensing agreement involving Pierre Fabre's recombinant humanized monoclonal antibody F50035, which targets the insulin-like growth factor (IGF-1) receptor; IGF-1 is overexpressed in various cancers including colon, breast, and prostate.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com